These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 19091002)

  • 1. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
    Hanson LR; Frey WH
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.
    Hanson LR; Frey WH
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):81-6. PubMed ID: 18040829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal treatment of neurodegenerative diseases and stroke.
    Gomez D; Martinez JA; Hanson LR; Frey WH; Toth CC
    Front Biosci (Schol Ed); 2012 Jan; 4(1):74-89. PubMed ID: 22202044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
    Garcia-Rodriguez JC; Sosa-Teste I
    ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery.
    Battaglia L; Panciani PP; Muntoni E; Capucchio MT; Biasibetti E; De Bonis P; Mioletti S; Fontanella M; Swaminathan S
    Expert Opin Drug Deliv; 2018 Apr; 15(4):369-378. PubMed ID: 29338427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: screening based on pharmacological and physiological properties.
    Pandya JD; Musyaju S; Modi HR; Okada-Rising SL; Bailey ZS; Scultetus AH; Shear DA
    J Transl Med; 2024 Feb; 22(1):167. PubMed ID: 38365798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
    Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
    Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving brain drug targeting through exploitation of the nose-to-brain route: a physiological and pharmacokinetic perspective.
    Badhan RK; Kaur M; Lungare S; Obuobi S
    Curr Drug Deliv; 2014; 11(4):458-71. PubMed ID: 24655046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia].
    Kamei N
    Yakugaku Zasshi; 2017; 137(10):1247-1253. PubMed ID: 28966266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review.
    Babu SR; Shekara HH; Sahoo AK; Harsha Vardhan PV; Thiruppathi N; Venkatesh MP
    Ther Deliv; 2023 Sep; 14(9):571-594. PubMed ID: 37691577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current advances in delivery of biotherapeutics across the blood-brain barrier.
    Rajadhyaksha M; Boyden T; Liras J; El-Kattan A; Brodfuehrer J
    Curr Drug Discov Technol; 2011 Jun; 8(2):87-101. PubMed ID: 21513485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease.
    Banks WA
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S2. PubMed ID: 19090999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases.
    Farhoudi M; Sadigh-Eteghad S; Mahmoudi J; Farjami A; Mahmoudian M; Salatin S
    Curr Pharm Des; 2022; 28(24):1985-2000. PubMed ID: 35676838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases.
    Meredith ME; Salameh TS; Banks WA
    AAPS J; 2015 Jul; 17(4):780-7. PubMed ID: 25801717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
    Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
    Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
    Dhuria SV; Hanson LR; Frey WH
    J Pharm Sci; 2010 Apr; 99(4):1654-73. PubMed ID: 19877171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.